Abstract: Described are non-invasive methods of detecting the presence of specific nucleic acid sequences as well as nucleic acid modifications and alterations by analyzing urine samples for the presence of transrenal nucleic acids. More specifically, the present invention encompasses methods of detecting specific fetal nucleic acid sequences and fetal sequences that contained modified nucleotides by analyzing maternal urine for the presence of fetal nucleic acids. The invention further encompasses methods of detecting specific nucleic acid modifications for the diagnosis of diseases, such as cancer and pathogen infections, and detection of genetic predisposition to various diseases. The invention specifically encompasses methods of analyzing specific nucleic acid modifications for the monitoring of cancer treatment. The invention further encompasses methods of analyzing specific nucleic acids in urine to track the success of transplanted cells, tissues and organs.
Type:
Grant
Filed:
August 3, 2000
Date of Patent:
December 10, 2002
Assignee:
Diagen Corporation
Inventors:
Samuil R. Umansky, Anatoly V. Lichtenstein, Hovsep S. Melkonyan
Abstract: Described are non-invasive methods of detecting the presence of specific nucleic acid sequences as well as nucleic acid modifications and alterations by analyzing urine samples for the presence of transrenal nucleic acids. More specifically, the present invention encompasses methods of detecting specific fetal nucleic acid sequences and fetal sequences that contained modified nucleotides by analyzing maternal urine for the presence of fetal nucleic acids. The invention further encompasses methods of detecting specific nucleic acid modifications for the diagnosis of diseases, such as cancer and pathogen infections, and detection of genetic predisposition to various diseases. The invention specifically encompasses methods of analyzing specific nucleic acid modifications for the monitoring of cancer treatment. The invention further encompasses methods of analyzing specific nucleic acids in urine to track the success of transplanted cells, tissues and organs.
Type:
Application
Filed:
November 7, 2001
Publication date:
August 29, 2002
Applicant:
Diagen Corporation
Inventors:
Samuil R. Umansky, Anatoly V. Lichtenstein, Hovsep S. Melkonyan
Abstract: Described are non-invasive methods of detecting and/or quantifying specific nucleic acid sequences by analyzing urine samples for nucleic acids that have crossed the kidney barrier. More specifically, the present invention encompasses methods of analyzing specific fetal nucleic acid sequences by analyzing maternal urine for the presence of fetal nucleic acids. The invention further encompasses methods of analyzing specific nucleic acid alterations for the diagnosis of disease. The invention encompasses methods of analyzing specific nucleic acid alterations for the diagnosis of cancer and the monitoring of its treatment. The invention further encompasses methods of analyzing specific nucleic acids in urine to track the success of transplanted cells, tissues and organs.
Type:
Grant
Filed:
July 3, 2000
Date of Patent:
September 11, 2001
Assignee:
Diagen Corporation
Inventors:
Samuil R. Umansky, Anatoly V. Lichtenstein, Hovsep S. Melkonyan
Abstract: Described are non-invasive methods of detecting the presence of specific nucleic acid sequences by analyzing urine samples for the presence of nucleic acids that have crossed the kidney barrier. More specifically, the present invention encompasses methods of detecting specific fetal nucleic acid sequences by analyzing maternal urine for the presence of fetal nucleic acids. The invention further encompasses methods of detecting specific nucleic acid alterations for the diagnosis of disease.
Type:
Grant
Filed:
February 4, 2000
Date of Patent:
June 26, 2001
Assignee:
Diagen Corporation
Inventors:
Samuil R. Umansky, Anatoly V. Lichtenstein, Hovsep S. Melkonyan
© 2024 Justia
